Biology › Section H · Gene expression and its regulation › Topic H.9
Cancer and gene regulation
Cancer is not one disease but a family of gene-control diseases: at every level where a cell regulates its genes — epigenetic marks, transcription factors, RNA stability, translation, protein modification — those controls can break. Tumor suppressors fall silent, proto-oncogenes get stuck on, and checkpoint proteins like cyclin B lose their grip. Understanding the breakage points now drives therapies that target a tumour's specific defects.
Cancer: a disease of altered gene expression
In cancer cells, mutations rewrite cell-cycle control so cells do not stop growing as they should, and they can also change a cell's growth rate or pace through the cycle. The deeper framing: cancer is, at its core, gene expression gone wrong. Genes that should be off switch on at high levels; genes that should be on fall silent — through mutation or through misregulation at any control point. No single cancer carries every error, but across cancers every level shows changes: histone acetylation (epigenetic), transcription-factor activation, RNA stability, translational control, and post-translational protein modification. Reading the layer where a particular tumour went wrong is the key to understanding it.
Checkpoints and the cyclin B case
Cells move through the cycle only by passing checkpoints — quality gates confirming each phase finished correctly and no dangerous mutation appeared. Many proteins police these gates, including cyclin B, and here control fails through modification: increased phosphorylation of cyclin B, a post-translational change, alters its function so it can no longer hold the checkpoint. The cell then cruises through the cycle unimpeded — even carrying mutations that should have terminated its growth. One added phosphate group, and the braking system is disabled; that is how a protein-modification defect contributes directly to cancer.
Tumor suppressors: the guardians
Normal cells carry tumor suppressor genes, active specifically to prevent excess, inappropriate growth. The most studied is p53, which carries mutations in more than half of all cancer types. The p53 protein is itself a transcription factor: it binds sites in the promoters of genes to launch their transcription. When p53 is mutated, the transcriptional activity of its many target genes shifts dramatically — genes that should respond to DNA damage or enforce a stop signal no longer do. Tumor suppressors are the cell's brakes, and cancer requires those brakes to fail; a single lost copy can separate a controlled from an uncontrolled lineage.
Proto-oncogenes: accelerators with a defect
Proto-oncogenes are the positive cell-cycle regulators — the accelerators. When mutated, they become oncogenes, and their overexpression drives uncontrolled growth, whether by altering another gene's transcription, its RNA stability, or its translation. The classic example is myc, a transcription factor aberrantly activated in Burkitt's lymphoma, a cancer of the lymph system. Overexpressed myc turns ordinary B cells into cancerous ones that keep dividing; their swelling numbers form tumours — Burkitt's patients can develop tumours of the jaw or mouth that interfere with eating. Where tumor suppressors fail by going quiet, oncogenes cause harm by shouting too loudly.
Epigenetic silencing in cancer cells
Cancer cells silence genes epigenetically very often — not by mutating them out, but by locking the chromatin. The signature: in the promoter region of a silenced gene, cytosines in CpG islands carry methyl groups, and the surrounding histones lack the acetylation marks that active genes carry. DNA methylation plus histone deacetylation together shut the gene off. But there is an opening: unlike mutations, these modifications are temporary and reversible. Drugs that block DNA methyltransferase enzymes or inhibit histone deacetylase (the protein stripping acetyl groups) can flip silenced genes back on — and reactivating a silenced tumour suppressor can help restore normal growth patterns, an active frontier of therapy design.
Transcriptional control gone wrong
Cancer arises here too. Mutations that activate transcription factors — for instance, added phosphorylation — increase a factor's grip on its promoter binding site, raising transcription of growth genes. Alternatively, the DNA itself mutates: a changed promoter or enhancer sequence can bind a factor more strongly, producing the same overexpression. Breast cancer supplies a worked case: in a subset of tumours, the epidermal growth factor receptor (EGFR) is overexpressed; the EGFR pathway activates protein kinases, which activate transcription factors controlling growth genes. New drugs that prevent EGFR activation were designed from exactly this understanding and are used to treat those cancers — regulation knowledge converted into therapy.
After transcription: miRNAs and splice forms
Post-transcriptional control fails in cancer as well. Several research groups have shown altered miRNA expression in specific cancers. Because miRNAs bind the 3' UTR of RNA molecules and promote their degradation, overexpressing them strips the RNA population and shrinks protein output; the miRNA set in breast cancer cells differs from lung cancer's and from normal breast cells — a fingerprint and a drug target: tumour-specific miRNAs could be switched off therapeutically. Translational and post-translational layers break too: in colon cancer, the cell-death mediator c-Flip appears in two forms, long and short. The long form, c-FLIPL, drives increased cell growth instead of the cell death it initiates in normal cells — the wrong splice variant flips a death signal into a growth signal.
Worked example: assembling one tumour's path
Build a plausible cancer sequence from the regulation layers, step by step. (1) A breast cell overexpresses EGFR, so growth-factor signalling runs hot. (2) The EGFR pathway activates protein kinases, which phosphorylate transcription factors, boosting transcription of growth-control genes. (3) Among the downstream effects, cyclin B becomes over-phosphorylated and loses its checkpoint function, so damaged cells slip through quality gates. (4) p53 is later mutated — its target genes no longer enforce stop signals or DNA-damage responses, removing the remaining brake. (5) Silencing of further tumour suppressors by CpG methylation completes the shift to uncontrolled growth. (6) Every step is a normal control mechanism subverted, not invented — which is why each step is also a potential drug target: block EGFR, restore p53 function, or demethylate the silenced suppressors.
Worked example: predicting two epigenetic drugs
Two new drugs enter a trial; predict their effects. (1) Drug A decreases DNA methylation: methyl groups stop accumulating on CpG cytosines in promoters, so chromatin around silenced tumour suppressors opens. (2) Drug B prevents acetyl groups from being removed from histones: deacetylation normally compacts chromatin and silences genes, so blocking it keeps histones acetylated and the underlying genes accessible. (3) Together, both drugs push silenced genes back toward expression — specifically restoring silenced tumour suppressors in the tumour. (4) The tumour logic: cancer cells often depend on those suppressors staying off; reactivation reinstates the growth control they disabled. (5) The general principle: epigenetic states are reversible by design, and drugs that bias the reversal can re-establish normal patterns.
Common mistakes to avoid
First, calling every cancer gene an oncogene — tumor suppressors are genes too, and they cause cancer by being lost or silenced, not amplified. Second, assuming p53 is a checkpoint protein itself — it is a transcription factor regulating target genes, which is why its mutation reshapes transcription so broadly. Third, thinking proto-oncogenes are dangerous as-is — they are normal positive regulators; only mutation converts them to oncogenes. Fourth, treating epigenetic silencing as permanent — methylation and deacetylation are reversible, the whole basis of several new therapies. Fifth, assuming one cancer shows every defect — different tumours break different layers; that heterogeneity is why expression profiling matters. Sixth, forgetting the c-Flip lesson — the same gene can help or harm depending on which splice form is expressed.
Key takeaways
Cancer is gene expression misregulated at every layer: mutations or misregulation can strike any control point, from CpG-methylation-driven epigenetic silencing through transcription-factor phosphorylation, miRNA-driven RNA decay, translational shifts, and post-translational modification. The guardians are tumor suppressors — p53, a transcription factor mutated in over half of all cancers — and their loss removes the brakes; the accelerators are proto-oncogenes, whose mutation into oncogenes (like myc in Burkitt's lymphoma) locks growth signalling on. Checkpoint control can fall to a single modification, as when phosphorylated cyclin B stops gating the cycle. The therapeutic payoff is personalised medicine: anti-EGFR drugs for EGFR-overexpressing breast tumours, demethylating and deacetylase-blocking drugs that reactivate silenced suppressors, and the prospect of miRNA-based drugs — each aimed at the layer a particular tumour broke.
Flashcards
Flashcard
Prevents uncontrolled growth
Test your understanding
Question 1 of 5
What is the normal function of tumor suppressor genes?
Question 2 of 5
How does a proto-oncogene become an oncogene?
Question 3 of 5
The epigenetic silencing commonly seen in cancer cells combines which two marks?
Question 4 of 5
Why can miRNA overexpression promote cancer?
Question 5 of 5
In the cyclin B example, how does increased phosphorylation contribute to cancer?
